The American laboratory Moderna announced Thursday that it intends to invest in its production lines to be able to produce up to 3 billion doses of its vaccine against Covid-19 in 2022.
The biotech, which has developed a vaccine based on innovative messenger RNA technology like Pfizer / BioNTech, has also raised its expectations for 2021 and now hopes to be able to provide between 800 million and 1 billion doses this year, has he said in a press release.
In detail, Moderna intends in particular to invest in the facilities of the Swiss group Lonza, one of the major suppliers to the pharmaceutical industry, and of the Spanish Rovi, which carries out the bottling.
The amount of these transactions, financed by the group’s treasury, was not disclosed.
“We are seeing that the virus is spreading quickly, we are seeing that the virus is mutating, we are seeing new variants appearing. (…) We have to take the lead to be ready if need be for a third dose. reminder “, underlined Thursday the European director of Moderna, Dan Staner, on the Swiss public channel RTS 1.
These investments will begin to produce their effects at the end of 2021 and the beginning of 2022.
Thus, Lonza announced Thursday morning that it was going to install three additional production lines at its site in Visp (in the Swiss canton of Valais), thus making it possible to double the production of substances intended for the manufacture of the Moderna vaccine.
Earlier this week, Sanofi, which is still working on its own vaccine, also revealed that it would bottle up to 200 million doses of Moderna’s vaccine against Covid-19, in order to meet global demand.
To do this, the French laboratory will put the infrastructure of its American site in Ridgefield (New Jersey) at the service of biotech for “filling and finishing operations of up to 200 million doses” from September.